

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6710984

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ARNE SCHOLZ	07/20/2020
RECEIVING PARTY DATA		
Name:	BAYER AKTIENGESELLSCHAFT	
Street Address:	KAISER-WILHELM-ALEE 1	
City:	LEVERKUSEN	
State/Country:	GERMANY	
Postal Code:	51373	
Name:	BAYER PHARMA AKTIENGESELLSCHAFT	
Street Address:	MÜLLERSTRASSE 178	
City:	BERLIN	
State/Country:	GERMANY	
Postal Code:	13353	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	16969460	
CORRESPONDENCE DATA		
Fax Number:	(650)493-6811	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(650) 493-9300	
Email:	patentdocket@wsgr.com, randico@wsgr.com	
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI	
Address Line 1:	650 PAGE MILL ROAD	
Address Line 4:	PALO ALTO, CALIFORNIA 94304	
ATTORNEY DOCKET NUMBER:	59362-782.831	
NAME OF SUBMITTER:	ROSE ANDICO	
SIGNATURE:	/Rose Andico/	
DATE SIGNED:	05/14/2021	
Total Attachments: 2		

source=Vincerx 59362-782.831 Executed Assignment#page1.tif

source=Vincerx 59362-782.831 Executed Assignment#page2.tif

ASSIGNMENT WITH DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)**ASSIGNMENT**

Whereas, I/We, the undersigned inventor(s) hereinafter called assignor(s), have invented certain improvements described in the application identified below; and

Whereas, 1) BAYER AKTIENGESELLSCHAFT

2) BAYER PHARMA AKTIENGESELLSCHAFT of 1) Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, DE

2) Müllerstrasse 178, 13353 Berlin, DE, (assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors, legal representatives, and assigns, my/our entire right, title and interest, if any, in the invention and the application for the United States of America, including all direct and indirect divisions, continuations, and continuations-in-part thereof, and all original, extended, reissued, reviewed, and reexamined Letters Patent of the United States, and all countries foreign thereto, that may be granted thereon, including rights of priority under the International Convention of Paris (1883) as amended, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we hereby agree that the assignee may apply for foreign Letters Patent on the invention and I/we will without further consideration, communicate all facts known to me/us and execute without further consideration all papers deemed necessary by the assignee in connection with the United States and foreign applications when called upon to do so by the assignee, its successors, legal representatives, or assigns. I/We further represent and warrant that I/We have the full right to convey the interest assigned by this assignment, and that I/We have not granted any rights inconsistent with the rights granted herein. I/We further acknowledge an obligation of assignment of this invention to assignee at the time the invention was made.

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

DECLARATION

As a below named inventor, I hereby declare that this assignment with declaration is directed to:

☐ The attached application, OR ☒ United States Application or PCT International Application
Number PCT/EP2019/053407 filed on 2019-02-12 (Confirmation No. _____).

PRE-AIA

My residence, mailing address, and citizenship are as stated below next to my name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention titled:

USE OF 5-FLUORO-4-{4-FLUORO-2-METHOXYPHENYL}-N-{4-[(S-METHYLSULFONIMIDOYL)METHYL]PYRIDIN-2-YL}PYRIDIN-2-AMINE FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POST-AIA

The above identified application was made or was authorized to be made by me.

I believe I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this assignment with declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

Authorization To Permit Access To Application by Participating Office

☐ If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified application is filed access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified application is filed to have access to the application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the application-as-filed with respect to: 1) the above-identified patent application-as-filed, 2) any foreign application to which the above-identified application claims priority under 35 USC 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application, and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Office.

FULL NAME OF INVENTOR:
RESIDENCE:
POST OFFICE ADDRESS:
CITIZENSHIP:
SIGNATURE / DATE

I. Arne SCHOLZ
10435 Berlin, DE
Schönhauser Allee 170, 10435 Berlin, DE
DE

20. JULI 2020